Next-Generation
System-Level Immune Reprogramming (XIRT)
Bridging the gap between Innate Sensing and Adaptive Killing.
Why Standard Therapies Fail
Solid tumors evolve to escape detection. In "Immune Deserts," the immune system ignores the cancer entirely. In "Excluded" tumors, a dense physical stroma blocks T-cells from entering.
Standard Checkpoint Inhibitors, Bispecific Antibodies, and CAR-T therapies cannot function in these environments because they lack the necessary substrate: active, infiltrating T-cells. To cure these cancers, we must do more than release a brake; we must initiate the engine of the Cancer-Immunity Cycle.
The OmniAntigen™ Advantage
We explicitly reject the "Prediction" model. While genetic (e.g., mRNA) therapies rely on algorithms to guess neoantigens, Novastra utilizes the hardware of the cancer cell itself.
-
Zero Prediction Error: By utilizing the whole autologous tumor cell, we capture the full spectrum of known and unknown neoantigens, including complex post-translational modifications that sequencing misses.
-
The Bio-Based Ignition: We use coordination chemistry to wrap the cell in a biocompatible nanocloak. This "Trojan Horse" remains stable in the blood but disassembles rapidly within the Dendritic Cell.
-
Profound Activation: Upon disassembly, the payload releases a precise concentration of Manganese and STING agonists. This exponentially sensitizes the cGAS-STING pathway, triggering a surge of Type I Interferons and chemotactic signals that recruit T-cells deep into the tumor core.
Built on World-Class Research
Our XIRT technology demonstrated transformative
efficacy in refractory disease models.
Biomarker Surge
Pre-clinical analysis revealed a profound upregulation of critical "Cold-to-Hot" mediators, including Type I Interferons (IFN-β), pro-inflammatory cytokines (IL-12, TNF-α), and T-cell
recruiting chemokines (CXCL10).
T-Cell Infiltration
The technology successfully converted "Excluded"
phenotypes into "Inflamed" environments, driving
a significantexpansion of infiltrating CD8+
Cytotoxic T-cells and CD80+ AntigenPresenting
Cells into the tumor bed.
Synergistic Efficacy
OIn aggressive melanoma models, the combination of
XIRT with checkpoint blockade resulted in highly effective
tumor suppression and complete regression
in responding subjects, significantly
outperforming single-agent controls.
A Decade of Pioneering Science
Novastra’s platform is built on a decade of continuous innovation in bio-based nanotechnology. Since 2014, our team has systematically advanced the field from the fundamental chemistry of cell-surface engineering to the creation of functional biohybrid therapeutics. This pioneering work, published in top peer-reviewed journals including Science (2018), Nature Nanotechnology (2016, 2025), Nature Communications (2022), Angewandte Chemie International Edition (2014, 2023, 2024, 2025) and more, has redefined how bio-based nanotechnology interacts with living biology. What began as a breakthrough in supramolecular assembly has evolved into today's clinical-stage XIRT platform, now validated to drive potent "Cold-to-Hot" immune reprogramming in the most challenging oncology settings.